Last reviewed 2026-04-20 · How we verify

low-dose CD20 monoclonal antibody injection

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Pyrexia
• White Blood Cells < 2000 cells/cm^3
• Absolute Neutrophil Count <1000 cells/cm^3
• Fatigue
• Nausea
• Platelets <50000 cells/cm^3
• Chills
• Hemoglobin <8.0 g/dL
• Arthralgia
• Vomiting
• Urticaria
• Myalgia

Key clinical trials

• Belimumab With Rituximab for Primary Membranous Nephropathy (PHASE2)
• Epcoritamab and Rituximab for First-line Follicular Lymphoma (PHASE2)
• A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma (PHASE1, PHASE2)
• Low-dose CD20 Monoclonal Antibody Injection in Preemptive Treatment of PTLD in Patients With EBV-HLH/CAEBV (NA)
• Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype (PHASE1, PHASE2)
• Study of Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas and Extended Study to Determine the Safety and Efficacy of Coulter Clone® 131Iodine-B1 Radioimmunotherapy of Advanced Non-Hodgkin's Lymphoma (PHASE1)
• Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.